IMUNON (NASDAQ: IMNN) has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to support further clinical and non-clinical development of IMNN-001, the company’s DNA-based IL-12 immunotherapy, with the NCI’s Cancer Therapy Evaluation Program (CTEP) assuming regulatory sponsorship.
According to IMUNON, IMNN-001 is the first gene-based immunotherapy selected by NCI/CTEP for partnered clinical development under a CRADA. Under the agreement, NCI investigators will evaluate IMNN-001 in new solid tumor indications and combination regimens, building on clinical data from the company’s ongoing ovarian cancer program.
In a statement, Stacy Lindborg, PhD, president and CEO of IMUNON, commented, “We believe our CRADA with NCI’s CTEP will explore the broad potential of IMNN-001 and our TheraPlas platform. This partnership allows us to efficiently explore new indications and combinations through the expertise of CTEP and the National Clinical Trials Network utilizing the centralized clinical trial infrastructure funded by NCI, while keeping our team fully focused on advancing our pivotal Phase 3 OVATION 3 study in frontline ovarian cancer as rapidly as possible.”
